Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AC Immune selected as Technology Pioneer 2009 and advances AD program

Dec. 10, 2008

Maas Biolab's intrathecal ciclosporin advances to phase II for ALS treatment

Dec. 10, 2008

Bayer's PDE9 inhibitor improves memory deficits in animal models

Dec. 10, 2008

Recent Takeda patent describes new agents for sleep disorders

Dec. 9, 2008

Magic Factor-1: A hepatocyte growth factor-derived partial Met agonist to counter muscle wasting

Dec. 9, 2008

Snapshots on T-type calcium channel antagonists discovered at Merck & Co.

Dec. 9, 2008

Targeting NR2 NMDA receptor subunit useful in early experimental parkinsonism

Dec. 9, 2008

Pozen reports positive top-line phase III results for PN-400

Dec. 5, 2008

INI treats first patient in phase I/II clinical trial of CellMed's CellBeads for stroke

Dec. 5, 2008

Gene therapy can restore arylsulfatase A expression, possibly treat metachromatic leukodystrophy

Dec. 5, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...